Vibativ® effectively helps treat secondary bacterial infections in covid-19 patients

Nashville, tenn., june 21, 2021 /prnewswire/ --cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of vibativ® (telavancin) in treating secondary bacterial infections in covid-19 patients – particularly those with other significant health problems, such as obesity, diabetes and heart disease.
CPIX Ratings Summary
CPIX Quant Ranking